List of Excipients in Branded Drug XERESE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	XERESE	acyclovir and hydrocortisone	0187-5104	CETOSTEARYL ALCOHOL	1969-12-31
Bausch Health US LLC	XERESE	acyclovir and hydrocortisone	0187-5104	CITRIC ACID MONOHYDRATE	1969-12-31
Bausch Health US LLC	XERESE	acyclovir and hydrocortisone	0187-5104	HYDROCHLORIC ACID	1969-12-31
Bausch Health US LLC	XERESE	acyclovir and hydrocortisone	0187-5104	ISOPROPYL MYRISTATE	1969-12-31

XERESE Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

XERESE is a prescription topical combination of acyclovir 5% and hydrocortisone 1% cream for the early treatment of recurrent herpes labialis. Its commercial value comes from combining antiviral activity with a low-strength corticosteroid in a single semisolid product. The main formulation opportunity is not a new active ingredient. It is a differentiated topical platform that improves skin feel, stability, delivery, packaging, adherence, and regulatory substitutability.

The product’s excipient system is conventional but commercially relevant. Cetyl and cetearyl alcohols provide structure and emollience; mineral oil and petrolatum create occlusion; propylene glycol supports moisturization and may assist solubilization; polyoxyl 20 cetostearyl ether acts as a nonionic emulsifier; sodium lauryl sulfate supports emulsification; and purified water forms the continuous aqueous phase.[1]

What is XERESE and how does its formulation work?

XERESE contains two active pharmaceutical ingredients:

Attribute	XERESE
Active ingredients	Acyclovir 5%; hydrocortisone 1%
Dosage form	Topical cream
Indication	Recurrent herpes labialis
Route	Cutaneous
Regulatory pathway	Prescription drug
FDA approval	NDA 022436, approved in 2009
Product category	Fixed-dose antiviral and corticosteroid combination
Biosimilar relevance	None; XERESE is a small-molecule topical drug

Acyclovir inhibits herpes simplex virus DNA polymerase after intracellular activation. Hydrocortisone reduces local inflammatory responses. The combination is intended for early application during recurrent cold sore episodes.[1]

The formulation must support two actives with different physicochemical profiles. Acyclovir has limited aqueous solubility and can be difficult to deliver uniformly in topical systems. Hydrocortisone is lipophilic and requires controlled dispersion or solubilization within the cream base. The excipient system therefore must maintain dose uniformity, physical stability, spreadability, and acceptable skin tolerability.

What excipients are used in XERESE cream?

The XERESE label identifies the following inactive ingredients:[1]

Excipient	Primary formulation function	Commercial significance
Cetyl alcohol	Emollient, consistency agent	Improves cream structure and skin feel
Cetostearyl alcohol	Emulsifying and thickening agent	Supports viscosity and physical stability
Mineral oil	Emollient and occlusive vehicle	Reduces water loss and improves glide
Polyoxyl 20 cetostearyl ether	Nonionic emulsifier	Helps stabilize the oil-in-water cream
Propylene glycol	Humectant and solvent	Supports hydration and may improve active dispersion
Sodium lauryl sulfate	Surfactant and emulsifier	Supports phase compatibility but can raise irritation concerns
White petrolatum	Occlusive emollient	Improves barrier effect and residence on skin
Purified water	Aqueous vehicle	Continuous phase of the cream

The system is materially different from a simple ointment. Petrolatum and mineral oil provide occlusion, while alcohols and surfactants create a spreadable emulsion. This balance is important for a product used on the lips and perioral skin, where excessive greasiness, whitening, tackiness, or stinging can reduce adherence.

Which excipients are most important for product performance?

The highest-value excipient decisions are likely the emulsifier package, the oil phase, the humectant level, and the rheology modifiers.

Acyclovir content uniformity can be affected by particle size, wetting, mixing energy, and the distribution of suspended or dissolved material. Hydrocortisone can be sensitive to crystal form, particle size, and partitioning between phases. The emulsifier and alcohol system must prevent phase separation and maintain consistent delivery throughout shelf life.

Sodium lauryl sulfate is functionally effective but may create a tolerability tradeoff. A commercial follow-on product could seek a lower-irritancy surfactant system, provided it maintains equivalent product performance and regulatory comparability.

What formulation patents protect XERESE?

XERESE protection is likely to involve a combination of regulatory exclusivity, product-specific patent rights, formulation know-how, manufacturing controls, and trademark protection. The active ingredients themselves are old and cannot provide meaningful composition-of-matter exclusivity.

The principal patent-sensitive concepts are:

1. A fixed-dose acyclovir and hydrocortisone combination.
2. Topical treatment of herpes labialis using an antiviral and corticosteroid.
3. Specific concentration ranges and dosing regimens.
4. Cream composition and excipient ratios.
5. Particle-size control, active distribution, or release characteristics.
6. Manufacturing processes that preserve uniformity and stability.

A definitive Orange Book conclusion must be based on the current FDA listing for NDA 022436 and associated U.S. patent records. The product label alone does not establish whether a patent is currently listed, expired, delisted, or no longer enforceable.[2] For commercial planning, the relevant distinction is between:

• Listed patents that may support a Paragraph IV challenge.
• Unlisted formulation or process patents that may still support separate infringement claims.
• Expired patents that no longer block launch.
• Trade secrets covering manufacturing parameters that cannot independently prevent an ANDA approval.

The most important commercial risk is usually not the existence of a historical formulation patent. It is whether a follow-on manufacturer can design around the claims while demonstrating pharmaceutical equivalence and acceptable topical performance.

When does XERESE lose exclusivity?

XERESE’s practical exclusivity depends on several separate dates:

Exclusivity or protection category	Relevance to XERESE
New chemical entity exclusivity	Not applicable to acyclovir or hydrocortisone
New combination exclusivity	May have supported initial approval, depending on FDA designation
Pediatric exclusivity	Relevant only if separately granted
Listed patent term	Depends on the specific patent and any term adjustment or extension
Regulatory exclusivity	Depends on the NDA’s FDA exclusivity record
Trademark	Does not prevent approval of an ANDA using a different name
Trade secrets	May slow replication but do not create statutory exclusivity

Because XERESE was approved in 2009, its original regulatory exclusivity periods would generally have expired by the mid-2010s unless a later statutory extension applied. The commercial barrier today is therefore likely to be patent scope, ANDA development complexity, and market economics rather than new chemical entity exclusivity.

What is the Orange Book status of XERESE?

The Orange Book determines whether FDA-listed patents and exclusivity periods affect abbreviated approval pathways.[2] For a topical combination product, an ANDA applicant must assess:

• Whether XERESE is listed as the reference listed drug.
• Whether the reference product has active patents.
• Whether the applicant can certify Paragraph III, Paragraph IV, or another applicable certification.
• Whether the formulation and route qualify for ANDA approval.
• Whether a suitability petition or 505(b)(2) pathway is needed.

A Paragraph IV certification could trigger patent litigation under the Hatch-Waxman framework. If the NDA holder files suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to the specific facts and court proceedings.[3]

For XERESE, the legal attractiveness of a Paragraph IV strategy depends on whether any remaining claims cover the entire acyclovir/hydrocortisone combination or only narrow formulation features. A broad method-of-use claim could be more difficult to design around than a claim limited to a particular cream base.

Which companies are challenging XERESE exclusivity?

The market does not present the same competitive structure as a high-revenue oral drug. XERESE competes with:

• Generic acyclovir creams and ointments.
• Over-the-counter docosanol products such as Abreva.
• Oral antiviral therapy, including acyclovir, valacyclovir, and famciclovir.
• Compounded acyclovir and corticosteroid preparations.
• Other topical products positioned around pain, itching, or lesion healing.

Publicly documented Paragraph IV activity and litigation should be confirmed through current FDA, PACER, and USPTO records. The absence of a highly visible generic challenge does not necessarily indicate strong patent protection. Low product revenue, limited market size, development costs, and uncertainty around topical bioequivalence can make a challenge economically unattractive.

What generic entry risks exist for XERESE?

A generic launch could occur through several pathways.

ANDA pathway

An ANDA is the most direct route if the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. For topical semisolids, FDA may expect comparative physicochemical characterization, product quality testing, and in vitro release testing. Depending on the product-specific requirements, clinical endpoint studies may also be required.[4]

The applicant would need to match or adequately characterize:

• Active ingredient strength.
• Dosage form and route.
• Container closure system.
• Microbial quality.
• Viscosity and rheology.
• Globule or particle-size distribution.
• pH and water activity.
• Drug release profile.
• Stability and impurity profile.

Exact excipient sameness may not always be required for an ANDA, but excipient differences can affect bioequivalence, irritation, release, and stability.

505(b)(2) pathway

A 505(b)(2) application may be more suitable for a materially different formulation, delivery system, or dosage form. Examples include a liposomal cream, an anhydrous balm, a hydrogel, a metered-dose pump, or a preservative-free system.

The 505(b)(2) route can create a differentiated product but may require additional clinical or bridging data. It also creates separate patent-certification and labeling issues.

Compounding and nonapproved alternatives

Compounded products can compete in limited settings but do not generally provide the same evidence package, manufacturing scale, or retail distribution as an FDA-approved product. They may be relevant to physician-directed use, but they are not a direct substitute for a commercially scalable generic.

What excipient strategies create commercial opportunities?

1. Lower-irritancy surfactant systems

Replacing or reducing sodium lauryl sulfate could improve tolerability, particularly for application near the lips. Candidate systems include milder nonionic surfactants, phospholipid emulsifiers, or self-emulsifying blends. The main technical challenge is preserving acyclovir distribution and hydrocortisone release.

2. Improved skin feel

A lighter cream, gel-cream, or quick-drying emulsion could compete against petrolatum-heavy products. Reducing residual greasiness may improve patient adherence, especially during daytime use.

Possible approaches include:

• Lower-viscosity emulsion systems.
• Volatile or semi-volatile emollients.
• Silicone-containing systems.
• Structured hydrogel emulsions.
• Lower-occlusion oil phases.

These changes would need careful evaluation because greater evaporation can increase crystallization risk and may reduce residence time.

3. Preservative-free packaging

A preservative-free product could target patients sensitive to preservatives or products used repeatedly around the mouth. Airless pumps, unit-dose packages, and laminated tubes can reduce contamination risk. Packaging would become part of the product’s formulation strategy rather than a simple container decision.

4. Improved delivery of acyclovir

Acyclovir’s limited solubility creates an opportunity for controlled particle engineering, micronization, nanodispersion, or alternative solvent systems. These technologies could improve uniformity and release without changing the active concentration.

The commercial value depends on whether the technology produces measurable advantages in release, stability, application frequency, or lesion outcomes.

5. Combination products with enhanced symptom control

A manufacturer could explore a topical combination that retains acyclovir and hydrocortisone but improves local comfort through a compatible anesthetic, cooling agent, or barrier-supporting excipient. Such changes could require a new regulatory strategy and create safety, labeling, and patent complications.

6. Packaging-led differentiation

A portable pump, precision applicator, or single-use sachet could reduce contamination and improve dosing consistency. A package that supports rapid application at the first sign of recurrence could have more practical value than a modest change in cream composition.

How strong is the XERESE patent estate?

The estate is likely moderate at best from a long-term blocking perspective because the active ingredients are off-patent and the product is a topical combination with a relatively narrow commercial market. Strength would depend on the breadth and remaining life of any formulation or method-of-use claims.

Patent estate factor	Assessment
Active ingredient protection	Weak; acyclovir and hydrocortisone are established compounds
Combination protection	Potentially meaningful if claims cover the specific dual-active therapy
Formulation protection	Potentially design-aroundable if claims depend on narrow excipient ranges
Method-of-use protection	Relevant if directed to recurrent herpes labialis and specific timing or dosing
Manufacturing protection	May protect process know-how but is harder to enforce against a finished generic
Regulatory exclusivity	Likely no longer the primary barrier
Generic substitution risk	Moderate, subject to FDA pathway and patent status
Commercial attractiveness	Niche, with opportunity for differentiated formulation rather than commodity pricing

The most defensible commercial assets may be trade secrets around particle control, mixing order, temperature profile, emulsification, filling, and stability. These assets can be difficult for a generic manufacturer to replicate exactly, but they do not necessarily prevent approval of an equivalent product.

What patent litigation affects XERESE?

A potential XERESE litigation case would likely involve:

• Paragraph IV certification against an Orange Book-listed patent.
• Claims concerning the acyclovir/hydrocortisone combination.
• Method-of-use claims for recurrent herpes labialis.
• Cream composition claims.
• Alleged infringement based on excipient selection or concentration ranges.

The commercial impact would depend on the filing date of the ANDA, the timing of litigation, the statutory stay, possible preliminary injunctions, and settlement terms. A settlement could allow an authorized generic, delayed entry, or launch under a noninfringing formulation.

No biosimilar litigation is relevant because XERESE is a small-molecule topical product, not a biologic. Any competitive litigation would be a generic-drug or branded topical dispute.

How does XERESE compare with competing treatments?

Product category	Active approach	Prescription status	Main competitive advantage
XERESE	Acyclovir plus hydrocortisone	Prescription	Dual antiviral and anti-inflammatory treatment
Acyclovir cream	Antiviral alone	Prescription in many markets	Lower formulation complexity and potential generic pricing
Docosanol cream	Viral-entry inhibition	OTC	Consumer access and retail availability
Oral valacyclovir	Systemic antiviral	Prescription	Convenient dosing and established use
Oral acyclovir	Systemic antiviral	Prescription	Low cost and broad availability
Compounded topical combinations	Variable	Compounded	Customization, but limited standardization

XERESE is most vulnerable where consumers prioritize OTC access, low price, or rapid self-treatment. Its strongest positioning is early, localized treatment for patients who value a prescription combination that addresses both viral replication and inflammation.

What are the revenue and licensing opportunities?

Standalone XERESE revenue is unlikely to match large primary-care or chronic-disease products. The commercial opportunity is better framed around portfolio expansion:

• Acquisition or licensing of a topical antiviral platform.
• Authorized-generic supply.
• Regional licensing in markets where prescription combination creams remain differentiated.
• Reformulation into a cosmetic-acceptable or preservative-free product.
• Contract development and manufacturing for branded or generic applicants.
• Combination-product lifecycle management.
• Specialty pharmacy or telehealth distribution.

Licensing value would depend on patent term, regulatory status, supply reliability, and whether the formulation has measurable clinical or usability advantages. A basic generic cream has limited strategic value unless it has a low-cost manufacturing position or preferred distribution access.

Key Takeaways

• XERESE combines acyclovir 5% and hydrocortisone 1% in a topical cream for recurrent herpes labialis.
• Its excipient system uses standard emollients, surfactants, emulsifiers, humectants, and an aqueous vehicle.
• The largest formulation opportunities are lower irritation, improved skin feel, preservative-free packaging, enhanced acyclovir delivery, and device-led dosing.
• Acyclovir and hydrocortisone provide little active-ingredient patent protection because both are established drugs.
• Any meaningful remaining protection would likely depend on combination, method-of-use, formulation, or manufacturing claims.
• Generic entry could proceed through an ANDA if the applicant meets topical bioequivalence and product-quality requirements.
• A materially differentiated cream or delivery system may require a 505(b)(2) strategy.
• XERESE has no biosimilar risk because it is not a biologic.
• Commercial value is more likely to come from lifecycle management, licensing, and differentiated topical technology than from a high-volume commodity generic.

FAQs

Can a generic XERESE use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the product remains pharmaceutically equivalent, meets applicable safety standards, and demonstrates bioequivalence. Excipients that alter release, irritation, stability, or active distribution can create regulatory complications.

Is a preservative-free XERESE formulation commercially viable?

Potentially. A preservative-free product could target sensitive-skin users and improve product positioning, but the package must control microbial contamination and preserve stability throughout use.

Would an XERESE gel have to use the same regulatory pathway as the cream?

Not necessarily. A materially different dosage form may require a 505(b)(2) application rather than an ANDA, particularly if the gel changes delivery, release, absorption, or clinical use.

Can a manufacturer avoid XERESE patents by changing the emulsifier?

Changing the emulsifier may avoid narrow composition claims, but it would not necessarily avoid broader combination or method-of-use claims. Patent design-around analysis must evaluate every asserted claim element.

Is XERESE suitable for an authorized-generic strategy?

It may be suitable for a targeted authorized-generic strategy where the reference sponsor controls supply, distribution, or formulation know-how. The opportunity is more likely to be niche and margin-sensitive than a large-scale generic launch.

References

1. DailyMed. (n.d.). XERESE- acyclovir and hydrocortisone cream: Prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards.
4. U.S. Food and Drug Administration. (2022). Acyclovir topical products: Draft product-specific guidance and topical dermatologic drug development guidance.